Literature DB >> 21977900

Alternative treatment of gluteofemoral fistulas using honey: a case report.

Paulina Vlcekova1, Barbora Krutakova, Peter Takac, Milan Kozanek, Juraj Salus, Juraj Majtan.   

Abstract

Perianal fistula is a common disease that affects particular patients with inflammatory bowel disease. Honey has been used as a natural remedy for centuries for the treatment of various disorders. We report a patient with persistent fistulas, in whom conventional medical and surgical therapy failed. In this case, most of fistulas in gluteofemoral region were completely healed and closed after 6 months of treatment with honey. In addition, honey reduced inflammation, pain and induration of affected region. This medical approach positively affected patient's mental condition and also improved his quality of life.
© 2011 The Authors. © 2011 Blackwell Publishing Ltd and Medicalhelplines.com Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21977900      PMCID: PMC7951016          DOI: 10.1111/j.1742-481X.2011.00844.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  12 in total

1.  The clinical course of fistulating Crohn's disease.

Authors:  S J Bell; A B Williams; P Wiesel; K Wilkinson; R C G Cohen; M A Kamm
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

2.  Fibrin glue treatment of complex anal fistulas has low success rate.

Authors:  Rasmy Loungnarath; David W Dietz; Matthew G Mutch; Elisa H Birnbaum; Ira J Kodner; James W Fleshman
Journal:  Dis Colon Rectum       Date:  2004-02-25       Impact factor: 4.585

Review 3.  Management of perianal Crohn's disease.

Authors:  Paul E Wise; David A Schwartz
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04       Impact factor: 11.382

4.  An assessment of the incidence of fistula-in-ano in four countries of the European Union.

Authors:  Carlo Zanotti; Carmen Martinez-Puente; Isabel Pascual; María Pascual; Dolores Herreros; Damián García-Olmo
Journal:  Int J Colorectal Dis       Date:  2007-06-07       Impact factor: 2.571

5.  Standardized antibacterial honey (Medihoney) with standard therapy in wound care: randomized clinical trial.

Authors:  Val Robson; Susanna Dodd; Stephen Thomas
Journal:  J Adv Nurs       Date:  2009-03       Impact factor: 3.187

6.  Honeydew honey as a potent antibacterial agent in eradication of multi-drug resistant Stenotrophomonas maltophilia isolates from cancer patients.

Authors:  Juraj Majtan; Lubica Majtanova; Jana Bohova; Viktor Majtan
Journal:  Phytother Res       Date:  2010-09-29       Impact factor: 5.878

7.  Randomized clinical trial of honey-impregnated dressings for venous leg ulcers.

Authors:  Andrew Jull; N Walker; V Parag; P Molan; A Rodgers
Journal:  Br J Surg       Date:  2008-02       Impact factor: 6.939

8.  Intramuscular injection-site complications.

Authors:  D J Greenblatt; M D Allen
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

9.  Manuka honey vs. hydrogel--a prospective, open label, multicentre, randomised controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers.

Authors:  Georgina Gethin; Seamus Cowman
Journal:  J Clin Nurs       Date:  2008-08-23       Impact factor: 3.036

10.  The patient with persistent perianal fistulae.

Authors:  Ioannis E Koutroubakis
Journal:  Best Pract Res Clin Gastroenterol       Date:  2007       Impact factor: 3.043

View more
  2 in total

1.  Honeybee glucose oxidase--its expression in honeybee workers and comparative analyses of its content and H2O2-mediated antibacterial activity in natural honeys.

Authors:  Marcela Bucekova; Ivana Valachova; Lenka Kohutova; Emanuel Prochazka; Jaroslav Klaudiny; Juraj Majtan
Journal:  Naturwissenschaften       Date:  2014-06-27

2.  Phytochemicals-mediated production of hydrogen peroxide is crucial for high antibacterial activity of honeydew honey.

Authors:  Marcela Bucekova; Monika Buriova; Ladislav Pekarik; Viktor Majtan; Juraj Majtan
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.